Sportswriters Love Marriotts More Than You Love Anything - Vocativ https://t.co/kuiRmBs5YH

5:38pm September 27th 2016 via Hootsuite

Color Genomics raises $45 million to provide cheaper genetic tests that detect cancer risk | TechCrunch https://t.co/2YUaYhsVdL

3:32pm September 27th 2016 via Hootsuite

The Simons Genome Diversity Project: 300 genomes from 142 diverse populations : Nature (PDF, OA) https://t.co/1KwIvlQVlt

10:27am September 27th 2016 via Hootsuite

Andrew Sullivan: My Distraction Sickness — and Yours | The Atlantic https://t.co/3fAlrpHB9U Great #longread on the need for silent space

2:00pm September 24th 2016 via Hootsuite

Diaz: MMR-proficient CRC: immed progression. Shows one case - in hospice, immed response. On opiods, had withdrawal. 2y alive #MAPonco16

11:42am September 24th 2016 via Hootsuite

Diaz: Pts w/CRC had to have failed 2 lines of Rx. Autoimmune AE; saw immed CEA biochemical response. #MAPonco16

11:41am September 24th 2016 via Hootsuite

Diaz: Microsatellites: reviews history, characteristics. Suggest: mutant-assoc'd neo-antigens (MANA). CRC w/Anti-PD1 #MAPonco16

11:39am September 24th 2016 via Hootsuite

Diaz: Hereditary HNPCC (Lynch Syndrome), goes through char's; Microsatellite instability (MSI); instability throughout genome #MAPonco16

11:37am September 24th 2016 via Hootsuite

Diaz: One dramatic responder to CRC. Germline (Lynch) or MMR sporadic (MLH1, MSH2, MSH6, PMS2, EpCAM) #MAPonco16

11:35am September 24th 2016 via Hootsuite

Luis Diaz (Johns Hopkins US): Somatic mutations as effective biomarkers and immunogens #MAPonco16

11:33am September 24th 2016 via Hootsuite

Snyder: Did T-cell receptor seq from Adaptive Biotech, also WES at 129x in tumor. Did see modest correl to APOBEC sig #MAPonco16

11:13am September 24th 2016 via Hootsuite

Snyder: Shows figure from Mellman '11 Nature https://t.co/CGS1osPLBH Moved to bladder ca w/anti-PD-L1; n=29 #MAPonco16

11:11am September 24th 2016 via Hootsuite

Snyder: Other studies show mutational load correlates to response; however exceptions occur #MAPonco16

11:09am September 24th 2016 via Hootsuite

Snyder: Checkpoint blockade for adv melanoma: reviews many studies. One '14 NEJM https://t.co/A7tPYYYlWu #MAPonco16

11:09am September 24th 2016 via Hootsuite

Alexandra Snyder (MSKCC) How to predict efficacy of Anti-PD(L)-1 #MAPonco16

11:06am September 24th 2016 via Hootsuite

Larkin: anti-CTLA4 Rx 'probably 'curative' in a small # of pts with adv melanoma; lots of work ahead on what combinations work #MAPonco16

11:00am September 24th 2016 via Hootsuite

Larkin: Toxicity: 'education is vital for all'; early assessment, intervention critical; multi-disciplinary, but led by oncology #MAPonco16

10:48am September 24th 2016 via Hootsuite

Larkin: Nivo alone vs Nivo + Ipi, combination high toxicity. 55% chance of bad side-effects #MAPonco16

10:44am September 24th 2016 via Hootsuite

Larkin: Taken further with PFS by tumor PD-L1 expression: HR of 0.87 (w/caution). Pt subgroups: poor responders data needed #MAPonco16

10:41am September 24th 2016 via Hootsuite

Larkin: Checkmate 067 trial '15 NEJM https://t.co/cMzkRG6qLt #MAPonco16

10:38am September 24th 2016 via Hootsuite

Larkin: Ipilimumab and the 'tail on the curve'; OS plateau's in year 3,4,5. Guardian piece: https://t.co/RD4x8TBvz7 #MAPonco16

10:36am September 24th 2016 via Hootsuite

Larkin: Interferon/IL-2 stimulation, now CTLA4/PD1 suppression. T-cell inhibitory receptors (blocking Abs), T-cell activating #MAPonco16

10:33am September 24th 2016 via Hootsuite

James Larkin (Royal Marsden UK) Overview of immunotherapies #MAPonco16

10:31am September 24th 2016 via Hootsuite

Anne-Mette Bjerregaard (Univ Denmark): MuPeXI a toolf or prediction of new epitopes #MAPonco16

10:22am September 24th 2016 via Hootsuite

Panel: Mughal comments that Sanger may be undercalling cancer mutations by some 20% #MAPonco16

9:58am September 24th 2016 via Hootsuite

Sotiriou: Case study, found FDFR2 VUS. TP53, known pathogenic, not actionable. DDR2: Unk sig. #MAPonco16

9:57am September 24th 2016 via Hootsuite

Sotiriou: New 10y clinical trial called AURORA for mBC '16 Oncogene ref https://t.co/m2hrafvIzm #MAPonco16

9:44am September 24th 2016 via Hootsuite

Charles Sotiriou (Universite Libre de Bruxelles) Case studies of precision oncology: the IJB (Jule Bordet Inst) Tumor Boad #MAPonco16

9:42am September 24th 2016 via Hootsuite

Lee: Clinical trials - Lung-MAP, FOne readout, also IHC for MET; SAFIR02 Luncg for PDL1 Rx. Shows list of TKI, MEK, EGFR, AKT #MAPonco16

9:35am September 24th 2016 via Hootsuite

Lee: RET xloc 1-2%; clinical trials ongoing. MET exon 14 skipping: exciting, but trials need to be done... #MAPonco16

9:31am September 24th 2016 via Hootsuite

Lee: Understanding resistence mechanisms; ROS rearr: crizotinib approved; PFS 17mos. Shows % incidence. MET exon 14 skip:2-3% #MAPonco16

9:30am September 24th 2016 via Hootsuite

Lee: ALK-inh in ALK-pos NSCLC. 2nd-gen inhibitors, even 3rd-gen. 1st: PFS 10mos; 2nd: PFS 20mos. as first-line. ASCO PFS HR .34 #MAPonco16

9:27am September 24th 2016 via Hootsuite

Lee: Like an HIV pt - as we understand how the mutation changes, combining multiple therapies. But more than EGFR... ALK next #MAPonco16

9:26am September 24th 2016 via Hootsuite

Lee: 2y survivor. 'It has transformed lung cancer trtmt'. 1st/2nd-gen TKI. 3rd-gen: PFS 18mos. Things are moving fast. #MAPonco16

9:25am September 24th 2016 via Hootsuite

Lee: 2y later: metastatis, EGFR exon 19 mut, ALK neg. EGFRinh, 15cycle, relapse. 1y later T790M confirmed, TIGER2 trial #MAPonco16

9:22am September 24th 2016 via Hootsuite

Lee: Typical case in his clinic - 66yo asian non-smoker, T2N1M0 lung adeno. Surgery, adjuvant chemo. 1 y later CT neg #MAPonco16

9:21am September 24th 2016 via Hootsuite

Lee: Lung cancer, 1.8M new cases/y. Leading cause of cancer death in men, 2nd cause in women. 80-85% NSCLC. UK 10y survival <5% #MAPonco1

9:20am September 24th 2016 via Hootsuite

Ming Lee (UCL, UK) Optimizing clinical care of patients with lung cancer #MAPonco16

9:19am September 24th 2016 via Hootsuite

Mughal: Onto cases that use FOne heme: 29yo female, gastric DLBCL, w/a RET fusion, and a IGH-BLC2, MYC ampl. #MAPonco16

9:16am September 24th 2016 via Hootsuite

Mughal: Now effort around AML '16 NEJM https://t.co/6LL87tKtuf And for DLBCL where 78% have potential actionable targets #MAPonco16

9:13am September 24th 2016 via Hootsuite

Mughal: Similarly, FOne Heme validation paper '16 Blood ref https://t.co/bNnqYexIEo #MAPonco16

9:09am September 24th 2016 via Hootsuite

Mughal: Points out Cancer Moonshot (US) and similar EU effort. FoundationOne analytical validation data: https://t.co/fc09mNuaZu #MAPonco16

9:08am September 24th 2016 via Hootsuite

Mughal: OS - reduced tumor burden to a very low level. No signs or symptoms. Not a 'cure' in purest sense. Operationally: yes #MAPonco16

9:04am September 24th 2016 via Hootsuite

Mughal: OS w/CML by treatment era ('82, '90, '95, '00, today). K-M curves over 10y to 92% survival. 20y ago: 8% #MAPonco16

9:04am September 24th 2016 via Hootsuite

Mughal: Shows photos of Janet Rowley and John Goldman and the impact their work on BCR-ABL Ph t9;22 https://t.co/VNeCsJtP19 #MAPonco16

9:02am September 24th 2016 via Hootsuite

Mughal: Early lesson from CML - the poster-child. Tamoxifen really was first for br ca but took 10y to be recognized as targeted #MAPonco16

9:00am September 24th 2016 via Hootsuite

Mughal: First heme (his talk), then Ming Lee (NSCLC) and the Christos Sotiriou (Breast Cancer) #MAPonco16

9:00am September 24th 2016 via Hootsuite